Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
MedPage Today on MSN
Sleep Disturbance in Chronic Spontaneous Urticaria
Impaired sleep had an effect on perception of disease severity in patients with chronic urticaria in the study. Higher ...
Explore the most influential drug approvals of 2025, highlighting FDA-cleared therapies that impact public health and clinical care.
MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes Ceragon Networks, Celldex, ...
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...
Apogee Therapeutics reports early trial data showing its asthma drug APG777 sharply reduced a key inflammation marker for up ...
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 ...
10don MSN
Regeneron stock lagged behind the S&P 500 last year. Why this firm moved off the sidelines.
Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ...
Biogen Inc. ( BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST ...
Zacks Investment Research on MSN
REGN soars 41% in six months: Is there more upside potential in 2026?
The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have surged 41% in this time frame, outpacing the industry’s growth of 22.4%. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback